Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 730 entries
Sorted by: Best Match Show Resources per page
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ohashi M, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I.
PMID: 28864997
Diabetes Ther. 2017 Oct;8(5):999-1013. doi: 10.1007/s13300-017-0292-1. Epub 2017 Sep 01.

INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are anti-diabetic agents that improve glycemic control with a low risk of hypoglycemia and ameliorate a variety of cardiovascular risk factors. The aim of the ongoing study described herein is to investigate the preventive...

Cite
Katakami N, Mita T, Yoshii H, et al. Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes Ther. 2017;8(5):999-1013doi: 10.1007/s13300-017-0292-1.
Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Umayahara, Y., Kaneto, H., Osonoi, T., Yamamoto, T., Kuribayashi, N., Maeda, K., Yokoyama, H., Kosugi, K., Ohtoshi, K., Hayashi, I., Sumitani, S., Tsugawa, M., Ohashi, M., Taki, H., Nakamura, T., Kawashima, S., Sato, Y., Watada, H., Shimomura, I. (2017). Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 8(5), 999-1013. https://doi.org/10.1007/s13300-017-0292-1
Katakami, Naoto, et al. "Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 8,5 (2017): 999-1013. doi: https://doi.org/10.1007/s13300-017-0292-1
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ohashi M, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I. Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. Diabetes Ther. 2017 Oct;8(5):999-1013. doi: 10.1007/s13300-017-0292-1. Epub 2017 Sep 01. PMID: 28864997; PMCID: PMC5630549.
Copy Download .nbib Format: NLM
Endoscopic diagnosis and treatment of early esophageal squamous neoplasia.

World journal of gastrointestinal endoscopy

Shimamura Y, Ikeya T, Marcon N, Mosko JD.
PMID: 28979708
World J Gastrointest Endosc. 2017 Sep 16;9(9):438-447. doi: 10.4253/wjge.v9.i9.438.

Esophageal cancer is one of the leading causes of cancer-related death and is associated with high morbidity and mortality. It carries a poor prognosis as more than half of patients present with advanced and unresectable disease. One contributing factor...

Cite
Shimamura Y, Ikeya T, Marcon N, et al. Endoscopic diagnosis and treatment of early esophageal squamous neoplasia. World J Gastrointest Endosc. 2017;9(9):438-447doi: 10.4253/wjge.v9.i9.438.
Shimamura, Y., Ikeya, T., Marcon, N., & Mosko, J. D. (2017). Endoscopic diagnosis and treatment of early esophageal squamous neoplasia. World journal of gastrointestinal endoscopy, 9(9), 438-447. https://doi.org/10.4253/wjge.v9.i9.438
Shimamura, Yuto, et al. "Endoscopic diagnosis and treatment of early esophageal squamous neoplasia." World journal of gastrointestinal endoscopy vol. 9,9 (2017): 438-447. doi: https://doi.org/10.4253/wjge.v9.i9.438
Shimamura Y, Ikeya T, Marcon N, Mosko JD. Endoscopic diagnosis and treatment of early esophageal squamous neoplasia. World J Gastrointest Endosc. 2017 Sep 16;9(9):438-447. doi: 10.4253/wjge.v9.i9.438. PMID: 28979708; PMCID: PMC5605343.
Copy Download .nbib Format: NLM
Cancer Stem Cells in the Thyroid.

Frontiers in endocrinology

Nagayama Y, Shimamura M, Mitsutake N.
PMID: 26973599
Front Endocrinol (Lausanne). 2016 Feb 29;7:20. doi: 10.3389/fendo.2016.00020. eCollection 2016.

The cancer stem cell (CSC) model posits that CSCs are a small, biologically distinct subpopulation of cancer cells in each tumor that have self-renewal and multi-lineage potential, and are critical for cancer initiation, metastasis, recurrence, and therapy-resistance. Numerous studies...

Cite
Nagayama Y, Shimamura M, Mitsutake N. Cancer Stem Cells in the Thyroid. Front Endocrinol (Lausanne). 2016;7:20doi: 10.3389/fendo.2016.00020.
Nagayama, Y., Shimamura, M., & Mitsutake, N. (2016). Cancer Stem Cells in the Thyroid. Frontiers in endocrinology, 720. https://doi.org/10.3389/fendo.2016.00020
Nagayama, Yuji, et al. "Cancer Stem Cells in the Thyroid." Frontiers in endocrinology vol. 7 (2016): 20. doi: https://doi.org/10.3389/fendo.2016.00020
Nagayama Y, Shimamura M, Mitsutake N. Cancer Stem Cells in the Thyroid. Front Endocrinol (Lausanne). 2016 Feb 29;7:20. doi: 10.3389/fendo.2016.00020. eCollection 2016. PMID: 26973599; PMCID: PMC4770029.
Copy Download .nbib Format: NLM
Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma.

Case reports in oncology

Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Ichikawa Y.
PMID: 27293400
Case Rep Oncol. 2016 Feb 19;9(1):134-7. doi: 10.1159/000443986. eCollection 2016.

A 49-year-old Japanese man had multiple huge masses (max. size 60 mm diameter) in his liver. These tumors were pathologically diagnosed by tumor biopsy as epithelioid hemangioendotheliomas of the liver. In this case, multiple liver tumors existed in both...

Cite
Kobayashi N, Shimamura T, Tokuhisa M, et al. Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case Rep Oncol. 2016;9(1):134-7doi: 10.1159/000443986.
Kobayashi, N., Shimamura, T., Tokuhisa, M., Goto, A., & Ichikawa, Y. (2016). Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case reports in oncology, 9(1), 134-7. https://doi.org/10.1159/000443986
Kobayashi, Noritoshi, et al. "Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma." Case reports in oncology vol. 9,1 (2016): 134-7. doi: https://doi.org/10.1159/000443986
Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Ichikawa Y. Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case Rep Oncol. 2016 Feb 19;9(1):134-7. doi: 10.1159/000443986. eCollection 2016. PMID: 27293400; PMCID: PMC4899657.
Copy Download .nbib Format: NLM
Chronic ileocolic intussusception due to transmural infiltration of diffuse large B cell lymphoma in a 14-year-old boy: a case report.

SpringerPlus

Saka R, Sasaki T, Matsuda I, Nose S, Onishi M, Fujino T, Shimomura H, Otsuka Y, Kajimoto N, Hirota S, Oue T.
PMID: 26207197
Springerplus. 2015 Jul 22;4:366. doi: 10.1186/s40064-015-1157-6. eCollection 2015.

Chronic intussusception, defined as intussusception continuing over 14 days, is rare in children. We herein report a case of chronic ileocolic intussusception caused by the transmural infiltration of diffuse large B cell lymphoma in a 14-year-old boy. The patient...

Cite
Saka R, Sasaki T, Matsuda I, et al. Chronic ileocolic intussusception due to transmural infiltration of diffuse large B cell lymphoma in a 14-year-old boy: a case report. Springerplus. 2015;4:366doi: 10.1186/s40064-015-1157-6.
Saka, R., Sasaki, T., Matsuda, I., Nose, S., Onishi, M., Fujino, T., Shimomura, H., Otsuka, Y., Kajimoto, N., Hirota, S., & Oue, T. (2015). Chronic ileocolic intussusception due to transmural infiltration of diffuse large B cell lymphoma in a 14-year-old boy: a case report. SpringerPlus, 4366. https://doi.org/10.1186/s40064-015-1157-6
Saka, Ryuta, et al. "Chronic ileocolic intussusception due to transmural infiltration of diffuse large B cell lymphoma in a 14-year-old boy: a case report." SpringerPlus vol. 4 (2015): 366. doi: https://doi.org/10.1186/s40064-015-1157-6
Saka R, Sasaki T, Matsuda I, Nose S, Onishi M, Fujino T, Shimomura H, Otsuka Y, Kajimoto N, Hirota S, Oue T. Chronic ileocolic intussusception due to transmural infiltration of diffuse large B cell lymphoma in a 14-year-old boy: a case report. Springerplus. 2015 Jul 22;4:366. doi: 10.1186/s40064-015-1157-6. eCollection 2015. PMID: 26207197; PMCID: PMC4508281.
Copy Download .nbib Format: NLM
Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated.

Journal of diabetes investigation

Osawa S, Yasuda T, Kaneto H, Shimo N, Yamamoto Y, Kawamori D, Miyatsuka T, Matsuoka TA, Shimomura I.
PMID: 25621140
J Diabetes Investig. 2015 Jan;6(1):105-6. doi: 10.1111/jdi.12251. Epub 2015 Jan 01.

No abstract available.

Cite
Osawa S, Yasuda T, Kaneto H, et al. Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated. J Diabetes Investig. 2015;6(1):105-6doi: 10.1111/jdi.12251.
Osawa, S., Yasuda, T., Kaneto, H., Shimo, N., Yamamoto, Y., Kawamori, D., Miyatsuka, T., Matsuoka, T. A., & Shimomura, I. (2015). Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated. Journal of diabetes investigation, 6(1), 105-6. https://doi.org/10.1111/jdi.12251
Osawa, Saeko, et al. "Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated." Journal of diabetes investigation vol. 6,1 (2015): 105-6. doi: https://doi.org/10.1111/jdi.12251
Osawa S, Yasuda T, Kaneto H, Shimo N, Yamamoto Y, Kawamori D, Miyatsuka T, Matsuoka TA, Shimomura I. Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated. J Diabetes Investig. 2015 Jan;6(1):105-6. doi: 10.1111/jdi.12251. Epub 2015 Jan 01. PMID: 25621140; PMCID: PMC4296710.
Copy Download .nbib Format: NLM
Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus.

Journal of diabetes investigation

Kuroda A, Kaneto H, Kawashima S, Sakamoto K, Takahara M, Shiraiwa T, Yasuda T, Katakami N, Matsuoka TA, Shimomura I, Matsuhisa M.
PMID: 24843634
J Diabetes Investig. 2013 Jan 29;4(1):78-81. doi: 10.1111/j.2040-1124.2012.00231.x. Epub 2012 Aug 21.

The aim of the present study was to compare the usefulness of premeal rapid-acting and regular insulin in type 2 diabetes patients. A total of 56 type 2 diabetic patients were investigated during hospitalization. Premeal rapid-acting insulin was applied...

Cite
Kuroda A, Kaneto H, Kawashima S, et al. Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus. J Diabetes Investig. 2012;4(1):78-81doi: 10.1111/j.2040-1124.2012.00231.x.
Kuroda, A., Kaneto, H., Kawashima, S., Sakamoto, K., Takahara, M., Shiraiwa, T., Yasuda, T., Katakami, N., Matsuoka, T. A., Shimomura, I., & Matsuhisa, M. (2013). Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus. Journal of diabetes investigation, 4(1), 78-81. https://doi.org/10.1111/j.2040-1124.2012.00231.x
Kuroda, Akio, et al. "Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus." Journal of diabetes investigation vol. 4,1 (2013): 78-81. doi: https://doi.org/10.1111/j.2040-1124.2012.00231.x
Kuroda A, Kaneto H, Kawashima S, Sakamoto K, Takahara M, Shiraiwa T, Yasuda T, Katakami N, Matsuoka TA, Shimomura I, Matsuhisa M. Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus. J Diabetes Investig. 2013 Jan 29;4(1):78-81. doi: 10.1111/j.2040-1124.2012.00231.x. Epub 2012 Aug 21. PMID: 24843634; PMCID: PMC4019291.
Copy Download .nbib Format: NLM
Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline.

Kidney international supplements

Hamano T, Nakano C, Obi Y, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Kusunoki Y, Rakugi H, Isaka Y, Tsubakihara Y, Colwell RK, Coddington JA.
PMID: 25019032
Kidney Int Suppl (2011). 2013 Dec;3(5):469-475. doi: 10.1038/kisup.2013.97.

The combination of serum 25-hydroxyvitamin D (25D) and fibroblast growth factor 23 (FGF23) levels predict hard renal outcomes in patients with chronic kidney disease (CKD), independent of classical markers of mineral and bone disorders, including serum phosphorus, parathyroid hormone,...

Cite
Hamano T, Nakano C, Obi Y, et al. Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl (2011). 2013;3(5):469-475doi: 10.1038/kisup.2013.97.
Hamano, T., Nakano, C., Obi, Y., Fujii, N., Matsui, I., Tomida, K., Mikami, S., Inoue, K., Shimomura, A., Kusunoki, Y., Rakugi, H., Isaka, Y., Tsubakihara, Y., Colwell, R. K., & Coddington, J. A. (2013). Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney international supplements, 3(5), 469-475. https://doi.org/10.1038/kisup.2013.97
Hamano, Takayuki, et al. "Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline." Kidney international supplements vol. 3,5 (2013): 469-475. doi: https://doi.org/10.1038/kisup.2013.97
Hamano T, Nakano C, Obi Y, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Kusunoki Y, Rakugi H, Isaka Y, Tsubakihara Y, Colwell RK, Coddington JA. Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl (2011). 2013 Dec;3(5):469-475. doi: 10.1038/kisup.2013.97. PMID: 25019032; PMCID: PMC4089736.
Copy Download .nbib Format: NLM
Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery.

Biochemistry and biophysics reports

Kizawa H, Nagao E, Shimamura M, Zhang G, Torii H.
PMID: 28955746
Biochem Biophys Rep. 2017 Apr 14;10:186-191. doi: 10.1016/j.bbrep.2017.04.004. eCollection 2017 Jul.

The liver plays a central role in metabolism. Although many studies have described

Cite
Kizawa H, Nagao E, Shimamura M, et al. Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. Biochem Biophys Rep. 2017;10:186-191doi: 10.1016/j.bbrep.2017.04.004.
Kizawa, H., Nagao, E., Shimamura, M., Zhang, G., & Torii, H. (2017). Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. Biochemistry and biophysics reports, 10186-191. https://doi.org/10.1016/j.bbrep.2017.04.004
Kizawa, Hideki, et al. "Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery." Biochemistry and biophysics reports vol. 10 (2017): 186-191. doi: https://doi.org/10.1016/j.bbrep.2017.04.004
Kizawa H, Nagao E, Shimamura M, Zhang G, Torii H. Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. Biochem Biophys Rep. 2017 Apr 14;10:186-191. doi: 10.1016/j.bbrep.2017.04.004. eCollection 2017 Jul. PMID: 28955746; PMCID: PMC5614670.
Copy Download .nbib Format: NLM
Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes.

Journal of pharmaceutical health care and sciences

Shimomura H, Andachi S, Aono T, Kigure A, Yamamoto Y, Miyajima A, Hirota T, Imanaka K, Majima T, Masuyama H, Tatsumi K, Aoyama T.
PMID: 26819743
J Pharm Health Care Sci. 2015 Nov 14;1:32. doi: 10.1186/s40780-015-0029-0. eCollection 2015.

BACKGROUND: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions. To date, however, there has been no report that...

Cite
Shimomura H, Andachi S, Aono T, et al. Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes. J Pharm Health Care Sci. 2015;1:32doi: 10.1186/s40780-015-0029-0.
Shimomura, H., Andachi, S., Aono, T., Kigure, A., Yamamoto, Y., Miyajima, A., Hirota, T., Imanaka, K., Majima, T., Masuyama, H., Tatsumi, K., & Aoyama, T. (2015). Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes. Journal of pharmaceutical health care and sciences, 132. https://doi.org/10.1186/s40780-015-0029-0
Shimomura, Hitoshi, et al. "Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes." Journal of pharmaceutical health care and sciences vol. 1 (2015): 32. doi: https://doi.org/10.1186/s40780-015-0029-0
Shimomura H, Andachi S, Aono T, Kigure A, Yamamoto Y, Miyajima A, Hirota T, Imanaka K, Majima T, Masuyama H, Tatsumi K, Aoyama T. Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes. J Pharm Health Care Sci. 2015 Nov 14;1:32. doi: 10.1186/s40780-015-0029-0. eCollection 2015. PMID: 26819743; PMCID: PMC4728759.
Copy Download .nbib Format: NLM
Ab initio quantum dynamical analysis of ultrafast nonradiative transitions via conical intersections in pyrazine.

Physical chemistry chemical physics : PCCP

Kanno M, Ito Y, Shimakura N, Koseki S, Kono H, Fujimura Y.
PMID: 25476139
Phys Chem Chem Phys. 2015 Jan 21;17(3):2012-24. doi: 10.1039/c4cp04807e. Epub 2014 Dec 05.

We theoretically investigated the mechanism of ultrafast nonradiative transition through conical intersections in photoexcited pyrazine by ab initio quantum dynamical calculations. This work was motivated by the recent theoretical and experimental studies that presented conflicting results: the former is...

Cite
Kanno M, Ito Y, Shimakura N, et al. Ab initio quantum dynamical analysis of ultrafast nonradiative transitions via conical intersections in pyrazine. Phys Chem Chem Phys. 2014;17(3):2012-24doi: 10.1039/c4cp04807e.
Kanno, M., Ito, Y., Shimakura, N., Koseki, S., Kono, H., & Fujimura, Y. (2015). Ab initio quantum dynamical analysis of ultrafast nonradiative transitions via conical intersections in pyrazine. Physical chemistry chemical physics : PCCP, 17(3), 2012-24. https://doi.org/10.1039/c4cp04807e
Kanno, Manabu, et al. "Ab initio quantum dynamical analysis of ultrafast nonradiative transitions via conical intersections in pyrazine." Physical chemistry chemical physics : PCCP vol. 17,3 (2015): 2012-24. doi: https://doi.org/10.1039/c4cp04807e
Kanno M, Ito Y, Shimakura N, Koseki S, Kono H, Fujimura Y. Ab initio quantum dynamical analysis of ultrafast nonradiative transitions via conical intersections in pyrazine. Phys Chem Chem Phys. 2015 Jan 21;17(3):2012-24. doi: 10.1039/c4cp04807e. Epub 2014 Dec 05. PMID: 25476139.
Copy Download .nbib Format: NLM
Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate.

Prostate international

Iwamoto H, Shigehara K, Miyagi T, Nakashima T, Shimamura M, Namiki M.
PMID: 26473153
Prostate Int. 2015 Sep;3(3):103-6. doi: 10.1016/j.prnil.2015.06.001. Epub 2015 Jul 17.

BACKGROUND: Prevalence of fluoroquinolone (FQ)-resistant Escherichia coli has been recently increasing worldwide. We analyzed the incidence and characteristics of acute bacterial prostatitis after transrectal ultrasound-guided needle prostate biopsy (TRUSP-Bx) with prophylactic tazobactam/piperacillin (TAZ/PIPC) treatment as an alternative regimen.METHODS: A...

Cite
Iwamoto H, Shigehara K, Miyagi T, et al. Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate. Prostate Int. 2015;3(3):103-6doi: 10.1016/j.prnil.2015.06.001.
Iwamoto, H., Shigehara, K., Miyagi, T., Nakashima, T., Shimamura, M., & Namiki, M. (2015). Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate. Prostate international, 3(3), 103-6. https://doi.org/10.1016/j.prnil.2015.06.001
Iwamoto, Hiroaki, et al. "Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate." Prostate international vol. 3,3 (2015): 103-6. doi: https://doi.org/10.1016/j.prnil.2015.06.001
Iwamoto H, Shigehara K, Miyagi T, Nakashima T, Shimamura M, Namiki M. Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate. Prostate Int. 2015 Sep;3(3):103-6. doi: 10.1016/j.prnil.2015.06.001. Epub 2015 Jul 17. PMID: 26473153; PMCID: PMC4588373.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 730 entries